Payment overview · 2025
General Payments
$406.02
10 reported records · 6 companies
Healthcare provider profile · identity verified
Kristin Spinelli
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · TOLEDO, OH · NPI 1134435027
Verified facts
What the public records show
CMS Open Payments records show Kristin Spinelli received $406.02 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $191.09 | 47.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.56 | 30.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.77 | 11.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.61 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.50 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.49 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.02 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $173.60 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $139.78 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 97 |
| Lisinopril | Lisinopril | 249 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 67 |
| Sertraline Hcl | Sertraline Hcl | 199 | 49 |
| Omeprazole | Omeprazole | 182 | 47 |
| Simvastatin | Simvastatin | 165 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 47 |
| Losartan Potassium | Losartan Potassium | 155 | 47 |
| Metformin Hcl | Metformin Hcl | 152 | 45 |
| Furosemide | Furosemide | 134 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 31 |
| Jardiance | Empagliflozin | 121 | 25 |
| Azithromycin | Azithromycin | 114 | 99 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 47 |
| Donepezil Hcl | Donepezil Hcl | 110 | 28 |
| Allopurinol | Allopurinol | 103 | 29 |
| Famotidine | Famotidine | 100 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 36 |
| Carvedilol | Carvedilol | 96 | 32 |
| Atenolol | Atenolol | 89 | 27 |
| Potassium Chloride | Potassium Chloride | 84 | 24 |
| Montelukast Sodium | Montelukast Sodium | 78 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 25 |
| Methylprednisolone | Methylprednisolone | 77 | 67 |
| Buspirone Hcl | Buspirone Hcl | 75 | 20 |
| Alprazolam | Alprazolam | 70 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Lorazepam | Lorazepam | 68 | 13 |
| Ozempic | Semaglutide | 67 | 16 |
| Celecoxib | Celecoxib | 66 | 14 |
| Glimepiride | Glimepiride | 66 | 21 |
| Alendronate Sodium | Alendronate Sodium | 64 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 58 |
| Metformin Hcl Er | Metformin Hcl | 63 | 16 |
| Spironolactone | Spironolactone | 63 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 17 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 17 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Glipizide | Glipizide | 48 | 13 |
| Tramadol Hcl | Tramadol Hcl | 48 | 15 |
| Bumetanide | Bumetanide | 46 | 12 |
| Ezetimibe | Ezetimibe | 44 | 16 |
| Prednisone | Prednisone | 44 | 18 |
| Clonidine Hcl | Clonidine Hcl | 41 | 16 |
| Eliquis | Apixaban | 41 | 14 |
| Gabapentin | Gabapentin | 39 | 21 |
| Meloxicam | Meloxicam | 39 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 31 |
| Cephalexin | Cephalexin | 36 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Trazodone Hcl | Trazodone Hcl | 30 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Repatha Syringe | Evolocumab | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Naproxen | Naproxen | 22 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Triazolam | Triazolam | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.02 · 10 records | ABBVIE INC. | AREXVY, BREZTRI, JARDIANCE, Kerendia, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error